Physician profile
Virendra Misra
NPI 1780648048
$2,268.29
in general payments reported to CMS, 2019-2025
28 companies · $772 in 2025
The $772 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $49.97 · 2021: $88.09 · 2022: $147 · 2023: $360 · 2024: $639 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $372.46 | 2023-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $359.08 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $288.81 | 2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $113.73 | 2024-2025 | Ponvory |
| Lundbeck LLC | $99.50 | 2024-2025 | Vyepti |
| Amgen INC. | $98.21 | 2019-2024 | Otezla, Repatha |
| Amneal Pharmaceuticals LLC | $97.15 | 2023-2024 | Rytary |
| Gilead Sciences, INC. | $96.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.84 | 2023-2025 | Jardiance |
| Ge Healthcare | $75.03 | 2024-2025 | |
| Genentech USA, INC. | $73.65 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $72.50 | 2019-2024 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $69.12 | 2019-2022 | |
| Tanabe Pharma America, INC. | $68.70 | 2024-2025 | Radicava |
| Pfizer INC. | $40.20 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.24 | 2020 | |
| Supernus Pharmaceuticals, INC. | $29.81 | 2021 | |
| Alnylam Pharmaceuticals INC. | $26.62 | 2022 | |
| Kyowa Kirin, INC. | $26.59 | 2021 | |
| Harmony Biosciences LLC | $20.49 | 2025 | |
| Lilly USA, LLC | $19.28 | 2025 | Kisunla |
| Axsome Therapeutics, INC. | $17.86 | 2025 | Symbravo |
| Avion Pharmaceuticals | $16.81 | 2022 | |
| Novo Nordisk INC | $16.14 | 2025 | Wegovy |
| Biogen, INC. | $16.11 | 2021 | |
| Allergan, INC. | $15.73 | 2020 | |
| Ucb, INC. | $15.56 | 2025 | Briviact |
| Abbott Laboratories | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virendra Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.